Prior work in a mouse model of obesity showed that treatment with a mineralocorticoid receptor antagonist, a drug with anti‐inflammatory effects in adipose tissue, reduced EAT SFA as measured by FAC MRI and increased perfusion reserve, which supports this hypothesis.20 This evidence concerns the gene NR3C2 and obesity due to melanocortin 4 receptor deficiency.